These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 34431970)
1. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. Batra G; Ghukasyan Lakic T; Lindbäck J; Held C; White HD; Stewart RAH; Koenig W; Cannon CP; Budaj A; Hagström E; Siegbahn A; Wallentin L; JAMA Cardiol; 2021 Dec; 6(12):1440-1445. PubMed ID: 34431970 [TBL] [Abstract][Full Text] [Related]
2. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. Held C; White HD; Stewart RAH; Budaj A; Cannon CP; Hochman JS; Koenig W; Siegbahn A; Steg PG; Soffer J; Weaver WD; Östlund O; Wallentin L; J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066452 [TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. Fanola CL; Morrow DA; Cannon CP; Jarolim P; Lukas MA; Bode C; Hochman JS; Goodrich EL; Braunwald E; O'Donoghue ML J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066436 [TBL] [Abstract][Full Text] [Related]
4. Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study. Amdur RL; Feldman HI; Dominic EA; Anderson AH; Beddhu S; Rahman M; Wolf M; Reilly M; Ojo A; Townsend RR; Go AS; He J; Xie D; Thompson S; Budoff M; Kasner S; Kimmel PL; Kusek JW; Raj DS; Am J Kidney Dis; 2019 Mar; 73(3):344-353. PubMed ID: 30545708 [TBL] [Abstract][Full Text] [Related]
5. ORBIT II sub-analysis: Impact of impaired renal function following treatment of severely calcified coronary lesions with the Orbital Atherectomy System. Lee MS; Lee AC; Shlofmitz RA; Martinsen BJ; Hargus NJ; Elder MD; Généreux P; Chambers JW Catheter Cardiovasc Interv; 2017 Apr; 89(5):841-848. PubMed ID: 27567020 [TBL] [Abstract][Full Text] [Related]
6. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336 [TBL] [Abstract][Full Text] [Related]
7. Impact of Mild-to-Moderate Chronic Kidney Disease on One Year Outcomes after Percutaneous Coronary Intervention. Grandjean-Thomsen NL; Marley P; Shadbolt B; Farshid A Nephron; 2017; 137(1):23-28. PubMed ID: 28478459 [TBL] [Abstract][Full Text] [Related]
8. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents. Sai E; Shimada K; Miyauchi K; Masaki Y; Kojima T; Miyazaki T; Kurata T; Ogita M; Tsuboi S; Yoshihara T; Miyazaki T; Ohsaka A; Daida H Heart Vessels; 2016 May; 31(5):694-701. PubMed ID: 25863806 [TBL] [Abstract][Full Text] [Related]
9. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. Baber U; Giustino G; Sartori S; Aquino M; Stefanini GG; Steg PG; Windecker S; Leon MB; Wijns W; Serruys PW; Valgimigli M; Stone GW; Dangas GD; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari D; Von Birgelen C; Mastoris I; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R JACC Cardiovasc Interv; 2016 Jan; 9(1):28-38. PubMed ID: 26762908 [TBL] [Abstract][Full Text] [Related]
10. Associations among chronic kidney disease, high total p-cresylsulfate and major adverse cardiac events. Wang CP; Lu LF; Yu TH; Hung WC; Chiu CA; Chung FM; Hsu CC; Lu YC; Lee YJ; Houng JY J Nephrol; 2013; 26(1):111-8. PubMed ID: 22460182 [TBL] [Abstract][Full Text] [Related]
11. Association of Serum Uromodulin with Death, Cardiovascular Events, and Kidney Failure in CKD. Steubl D; Schneider MP; Meiselbach H; Nadal J; Schmid MC; Saritas T; Krane V; Sommerer C; Baid-Agrawal S; Voelkl J; Kotsis F; Köttgen A; Eckardt KU; Scherberich JE; Clin J Am Soc Nephrol; 2020 May; 15(5):616-624. PubMed ID: 32291270 [TBL] [Abstract][Full Text] [Related]
12. Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. Correa S; Morrow DA; Braunwald E; Davies RY; Goodrich EL; Murphy SA; Cannon CP; O'Donoghue ML J Am Heart Assoc; 2018 Oct; 7(20):e009077. PubMed ID: 30371283 [TBL] [Abstract][Full Text] [Related]